Scotland has taken the lead in the UK by introducing screening for a rare condition that causes progressive muscle degeneration in babies, a move welcomed by parents as groundbreaking. Spinal muscular atrophy (SMA) can lead to muscle weakness, breathing difficulties, swallowing problems, and impaired mobility in children. Early detection of SMA can help prevent its most severe consequences. On average, around three to four babies are born with SMA in Scotland each year.
All parents will now have the opportunity to have their newborns screened for SMA using the existing blood spot test typically done around the fourth day after birth. This step marks a significant advancement in The Mirror’s campaign, initiated five years ago, advocating for nationwide screening of newborns for SMA. Former Little Mix member Jesy Nelson, whose twins have SMA, united with the cause earlier this year to push for comprehensive testing of all babies.
Jesy’s personal experience with her daughters, who were diagnosed with SMA too late to prevent irreversible nerve damage, prompted her to launch a petition through The Mirror urging the UK government to fund routine SMA testing within the NHS. The petition has garnered nearly 150,000 signatures. Parents Tony and Carrie Pearson have been campaigning for a national screening program following their daughter Grayce’s SMA diagnosis at six months old.
Carrie expressed gratitude that future children will benefit from early detection, treatment, and milestone achievements, reducing the distress and anxiety that families like theirs had to endure. Tony emphasized the historic significance of Scotland’s pilot program for SMA screening, highlighting the minimal cost per baby test compared to its potential life-saving impact.
Dr. Sarah Smith, the director of the Glasgow screening laboratory, stressed the importance of identifying SMA in infants before symptoms manifest to prevent muscle deterioration. The lab, which currently screens for 10 disorders, will now include SMA in its screening program. The goal is to detect SMA pre-symptomatically, initiate timely treatment, and enhance the quality of life for affected babies.
Funding for the two-year screening initiative is provided by the Scottish Government and pharmaceutical company Novartis, totaling £530,000.